Bellicum Pharmaceuticals, Inc. (BLCM) Financial Statements (2024 and earlier)

Company Profile

Business Address 3730 KIRBY DRIVE
HOUSTON, TX 77098
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,83746,15635,49591,02892,99938,839
Cash and cash equivalents21,83746,15635,49591,02843,69538,839
Short-term investments     49,304 
Restricted cash and investments  1,5011,5012,788  
Asset, held-for-sale, not part of disposal group   1,64316,851  
Other undisclosed current assets1,9641,4748041,1872,29662,811
Total current assets:23,80149,13139,443111,85495,295101,650
Noncurrent Assets
Operating lease, right-of-use asset   6451,042
Property, plant and equipment22121892,52920,87825,942
Long-term investments and receivables      1,368
Long-term investments      1,368
Restricted cash and investments     4,9736,190
Other noncurrent assets   307825355378
Total noncurrent assets:22121,1414,39626,20633,878
TOTAL ASSETS:23,82349,14340,584116,250121,501135,528
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,4773,8494,1659,77012,3639,679
Employee-related liabilities3201,0292,032  
Accounts payable486   3,7743,287
Accrued liabilities2,477   8,5896,392
Other undisclosed accounts payable and accrued liabilities(486)3,5293,1367,738  
Debt    11,0004031
Deferred rent credit     418
Derivative instruments and hedges, liabilities8092,77310,34552,184  
Deferred revenue and credits2,446
Contract with customer, liability2,983
Other undisclosed current liabilities 4869010,19121,464  
Total current liabilities:3,7726,71224,70194,41815,80412,156
Noncurrent Liabilities
Long-term debt and lease obligation    25,71735,92335,077
Long-term debt, excluding current maturities    25,71735,83234,946
Capital lease obligations91131
Liabilities, other than long-term debt     1,2963,647
Deferred revenue and credits3,647
Deferred rent credit     1,296
Other undisclosed noncurrent liabilities   344864  
Total noncurrent liabilities:   34426,58137,21938,724
Other undisclosed liabilities      
Total liabilities:3,7726,71225,045120,99953,02350,880
Temporary equity, carrying amount18,03618,03618,03621,468  
Equity
Equity, attributable to parent2,01524,395(2,497)(26,217)68,47884,648
Common stock878584507442340
Treasury stock, value(5,056)(5,056)(5,056)(5,056)(5,056)(5,056)
Additional paid in capital582,763580,156543,561511,684493,784411,922
Accumulated other comprehensive loss(354)(338)(339)(327)(144)(46)
Accumulated deficit(575,425)(550,452)(540,747)(533,025)(420,548)(322,512)
Total equity:2,01524,395(2,497)(26,217)68,47884,648
TOTAL LIABILITIES AND EQUITY:23,82349,14340,584116,250121,501135,528

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1,500322,3917,1431,639185
Revenue, net185
Net investment income 32 1,3511,639 
Other operating income   2,391   
Cost of revenue
(Cost of Goods and Services Sold)
     (436) 
Gross profit:1,500322,3917,1431,203185
Operating expenses(28,481)(30,588)(54,583)(94,507)(96,586)(87,572)
Other operating income (expense), net (478)    
Other undisclosed operating income (loss) 6,168500 (83) 
Operating loss:(26,981)(24,866)(51,692)(87,364)(95,466)(87,387)
Nonoperating income (expense)2,01015,16143,970(25,113)(2,570)(4,392)
Interest and debt expense  (4)112(4,280)(4,199)(1,786)
Loss from continuing operations before income taxes:(24,971)(9,709)(7,610)(116,757)(102,235)(93,565)
Income tax expense (2)     
Other undisclosed loss from continuing operations      
Loss from continuing operations:(24,973)(9,709)(7,610)(116,757)(102,235)(93,565)
Loss before gain (loss) on sale of properties:(9,709)(7,610)(116,757)(102,235)(93,565)
Net loss:(24,973)(9,709)(7,610)(116,757)(102,235)(93,565)
Other undisclosed net income (loss) attributable to parent  4(112)4,2804,1991,786
Net loss available to common stockholders, diluted:(24,973)(9,705)(7,722)(112,477)(98,036)(91,779)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(24,973)(9,709)(7,610)(116,757)(102,235)(93,565)
Other comprehensive loss    (112,660)(98,134)(91,842)
Comprehensive loss:(24,973)(9,709)(7,610)(229,417)(200,369)(185,407)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(16)5(124)116,757102,23593,565
Comprehensive loss, net of tax, attributable to parent:(24,989)(9,704)(7,734)(112,660)(98,134)(91,842)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: